Controversial doctor Vinay Prasad named CBER director, STAT reports
New Appointment at FDA: Vinay Prasad has been appointed as the new director of the Center for Biologics Evaluation and Research at the FDA, overseeing vaccine and gene therapy regulation, despite his previous criticisms of the medical mainstream.
Market Reaction: Following the announcement, the SPDR S&P Biotech ETF dropped 5%, affecting various biotech stocks including Sarepta, Moderna, and Novavax.
Trade with 70% Backtested Accuracy
Analyst Views on SRPT
About SRPT
About the author
Capricor's Former Executive Considered for FDA Biologics Chief
- FDA Decision Approaches: Capricor is awaiting an FDA decision on its DMD treatment Deramiocel, expected by August 22, which will directly impact the company's market performance and investor confidence.
- Clinical Data Support: The resubmission included results from the Hope-3 trial, showing a 54% slower deterioration in upper-limb function and a 91% slowing of cardiac disease progression, providing strong statistical support for the drug's approval.
- Executive Transition Impact: Former VP Houman Hemmati is being considered for the FDA's Center for Biologics Evaluation and Research, which could improve approval prospects for Capricor and other biotech firms, as reflected by a 1% rise in stock price during premarket trading.
- Market Sentiment Shift: With Hemmati's potential appointment, retail sentiment for Capricor shifted from 'bearish' to 'bullish', with expectations that the stock could exceed $75 upon approval, indicating a positive outlook for the company's future.
SAREPTA THERAPEUTICS INC: RBC Increases Target Price from $18 to $19
Company Overview: Sarepta Therapeutics is a biotechnology company focused on developing innovative therapies for rare diseases, particularly in the field of genetic medicine.
Stock Price Update: RBC Capital Markets has raised the target price for Sarepta Therapeutics' stock from $18 to $19, indicating a positive outlook for the company's future performance.
SAREPTA THERAPEUTICS, INC.: DEUTSCHE BANK INCREASES TARGET PRICE FROM $12 TO $14
Company Overview: Sarepta Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases.
Recent Financial Update: Deutsche Bank has raised the target price for Sarepta Therapeutics from $12 to $14, indicating a positive outlook for the company's stock.
SAREPTA THERAPEUTICS INC: WEDBUSH INCREASES TARGET PRICE FROM $29 TO $35
Company Overview: Sarepta Therapeutics is a biotechnology company focused on developing innovative therapies for rare diseases, particularly in the field of genetic medicine.
Recent Price Increase: The company has raised its target price to $35 from a previous target of $29, indicating a positive outlook from analysts.
Market Impact: This price adjustment reflects growing confidence in Sarepta's pipeline and potential market performance.
Investor Sentiment: The increase in target price may influence investor sentiment and trading activity surrounding Sarepta Therapeutics' stock.
SAREPTA THERAPEUTICS INC: CITIGROUP INCREASES TARGET PRICE FROM $9 TO $13
Company Overview: Sarepta Therapeutics is a biotechnology company focused on developing innovative therapies for rare diseases, particularly in the field of genetic medicine.
Stock Price Increase: Citigroup has raised the price target for Sarepta Therapeutics' stock from $9 to $13, indicating a positive outlook on the company's future performance.
SAREPTA THERAPEUTICS INC: PIPER SANDLER INCREASES TARGET PRICE FROM $16 TO $23
Company Overview: Sarepta Therapeutics is a biotechnology company focused on developing innovative therapies for rare diseases, particularly in the field of genetic medicine.
Stock Price Increase: The company has raised its target price from $16 to $23, indicating a positive outlook and potential growth in its market valuation.
Capricor's Former Executive Considered for FDA Biologics Chief
- FDA Decision Approaches: Capricor is awaiting an FDA decision on its DMD treatment Deramiocel, expected by August 22, which will directly impact the company's market performance and investor confidence.
- Clinical Data Support: The resubmission included results from the Hope-3 trial, showing a 54% slower deterioration in upper-limb function and a 91% slowing of cardiac disease progression, providing strong statistical support for the drug's approval.
- Executive Transition Impact: Former VP Houman Hemmati is being considered for the FDA's Center for Biologics Evaluation and Research, which could improve approval prospects for Capricor and other biotech firms, as reflected by a 1% rise in stock price during premarket trading.
- Market Sentiment Shift: With Hemmati's potential appointment, retail sentiment for Capricor shifted from 'bearish' to 'bullish', with expectations that the stock could exceed $75 upon approval, indicating a positive outlook for the company's future.
SAREPTA THERAPEUTICS INC: RBC Increases Target Price from $18 to $19
Company Overview: Sarepta Therapeutics is a biotechnology company focused on developing innovative therapies for rare diseases, particularly in the field of genetic medicine.
Stock Price Update: RBC Capital Markets has raised the target price for Sarepta Therapeutics' stock from $18 to $19, indicating a positive outlook for the company's future performance.
SAREPTA THERAPEUTICS, INC.: DEUTSCHE BANK INCREASES TARGET PRICE FROM $12 TO $14
Company Overview: Sarepta Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases.
Recent Financial Update: Deutsche Bank has raised the target price for Sarepta Therapeutics from $12 to $14, indicating a positive outlook for the company's stock.
SAREPTA THERAPEUTICS INC: WEDBUSH INCREASES TARGET PRICE FROM $29 TO $35
Company Overview: Sarepta Therapeutics is a biotechnology company focused on developing innovative therapies for rare diseases, particularly in the field of genetic medicine.
Recent Price Increase: The company has raised its target price to $35 from a previous target of $29, indicating a positive outlook from analysts.
Market Impact: This price adjustment reflects growing confidence in Sarepta's pipeline and potential market performance.
Investor Sentiment: The increase in target price may influence investor sentiment and trading activity surrounding Sarepta Therapeutics' stock.
SAREPTA THERAPEUTICS INC: CITIGROUP INCREASES TARGET PRICE FROM $9 TO $13
Company Overview: Sarepta Therapeutics is a biotechnology company focused on developing innovative therapies for rare diseases, particularly in the field of genetic medicine.
Stock Price Increase: Citigroup has raised the price target for Sarepta Therapeutics' stock from $9 to $13, indicating a positive outlook on the company's future performance.
SAREPTA THERAPEUTICS INC: PIPER SANDLER INCREASES TARGET PRICE FROM $16 TO $23
Company Overview: Sarepta Therapeutics is a biotechnology company focused on developing innovative therapies for rare diseases, particularly in the field of genetic medicine.
Stock Price Increase: The company has raised its target price from $16 to $23, indicating a positive outlook and potential growth in its market valuation.
